These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21323897)

  • 1. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine.
    Jharap B; de Boer N; Vos R; Smid K; Zwiers A; Peters G; Mulder C; Wilhelm A; van Bodegraven A
    Br J Pharmacol; 2011 Jun; 163(4):722-31. PubMed ID: 21323897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited intra-individual variability in hypoxanthine-Guanine phosphoribosyl transferase, thiopurine S-methyl transferase, and xanthine oxidase activity in inflammatory bowel disease patients during 6-thioguanine therapy.
    van Asseldonk DP; de Boer NK; Smid K; Mulder CJ; van Bodegraven AA; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):284-90. PubMed ID: 20544508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
    Seinen ML; van Asseldonk DP; de Boer NK; Losekoot N; Smid K; Mulder CJ; Bouma G; Peters GJ; van Bodegraven AA
    J Crohns Colitis; 2013 Nov; 7(10):812-9. PubMed ID: 23317929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine.
    Bayoumy AB; Mulder CJJ; Loganayagam A; Sanderson JD; Anderson S; Boekema PJ; Derijks LJJ; Ansari AR
    Ther Drug Monit; 2021 Oct; 43(5):617-623. PubMed ID: 34521801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
    Gao X; Zhang FB; Ding L; Liu H; Wang XD; Chen BL; Bi HC; Xiao YL; Zhao LZ; Chen MH; Huang M; Hu PJ
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease.
    Ding L; Zhang FB; Liu H; Gao X; Bi HC; Wang XD; Chen BL; Zhang Y; Zhao LZ; Zhong GP; Hu PJ; Chen MH; Huang M
    Inflamm Bowel Dis; 2012 Jan; 18(1):63-73. PubMed ID: 21381155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease.
    de Boer NK; Derijks LJ; Keizer-Garritsen JJ; Lambooy LH; Ruitenbeek W; Hooymans PM; van Bodegraven AA; de Jong DJ
    J Clin Pharmacol; 2007 Feb; 47(2):187-91. PubMed ID: 17244769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
    Armstrong L; Sharif JA; Galloway P; McGrogan P; Bishop J; Russell RK
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1106-14. PubMed ID: 21929546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine.
    Lee MN; Kang B; Choi SY; Kim MJ; Woo SY; Kim JW; Choe YH; Lee SY
    Inflamm Bowel Dis; 2015 May; 21(5):1054-62. PubMed ID: 25851563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease.
    Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    J Crohns Colitis; 2018 Feb; 12(3):298-305. PubMed ID: 29145599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.
    Derijks LJ; Gilissen LP; Engels LG; Bos LP; Bus PJ; Lohman JJ; Curvers WL; Van Deventer SJ; Hommes DW; Hooymans PM
    Ther Drug Monit; 2004 Jun; 26(3):311-8. PubMed ID: 15167634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis.
    Wusk B; Kullak-Ublick GA; Rammert C; von Eckardstein A; Fried M; Rentsch KM
    Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1407-13. PubMed ID: 15618853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
    Kang B; Kim TJ; Choi J; Baek SY; Ahn S; Choi R; Lee SY; Choe YH
    Aliment Pharmacol Ther; 2020 Aug; 52(3):459-470. PubMed ID: 32598049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of 6-Thioguanine Nucleotide Metabolite Monitoring in Inflammatory Bowel Disease Patients Treated with Azathioprine.
    Pavlovska K; Petrushevska M; Gjorgjievska K; Zendelovska D; Ribarska JT; Kikerkov I; Gjatovska LL; Atanasovska E
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2019 May; 40(1):73-79. PubMed ID: 31152640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.